Genomic Vision célèbre le succès de son introduction en Bourse sur Euronext Paris

Back

-IPO raises €23 million-
- 4.7x oversubscribed, with total demand at €93.9 million-

Paris 7 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1],today congratulated Genomic Vision,a biotechnology company specialising in molecular diagnostics for genetic diseases, on its successful listing in compartment C of Euronext’s regulated market in Paris.

Genomic Vision is a molecular diagnostics company that develops and markets diagnostic tests and research tools based on analysing individual DNA molecules. To do so, it uses the “molecular combing” technology discovered by Aaron Bensimon, Chairman of the Executive Board and co-founder of Genomic Vision, who was working at the time at the Institut Pasteur’s Unité de Stabilité des Génomes unit in collaboration with a research team from Ecole Normale Supérieure. This cutting-edge technology detects quantitative and qualitative variations in the genome and establishes their role in a given pathology. The company focuses primarily on oncogenetics, the main market for genetic testing.

Genomic Vision (ticker symbol: GV) was listed through a Global Offering[2]. Given very strong demand — a total €93.9 million — the company decided to fully exercise the extension option. The admission and issue price of Genomic Vision shares was set at €15.00, in the middle of the indicative price range.

Altogether 1,533,332 shares were issued, raising a total of €23 million before any exercise of the over-allotment option. Based on a total 4,266,907 shares admitted to trading at €15 per share, Genomic Vision’s market capitalisation stands at €64 million.

The settlement  and delivery of the Offering occurred on 4 April 2014. From April 2 through April 4, Genomic Vision shares were traded on an “as-if-and-when-issued” basis.

“We would like to extend a warm welcome to Genomic Vision, and are proud to help raise capital for a growth company specialised in diagnostics for genetic diseases and cancer. Its listing testifies to the very dynamic market for IPOs. Genomic Vision will be able to draw on EnterNext’s advice and services as it makes the most of its presence on the stock market,” said Eric Forest, Chairman and CEO of EnterNext.

Aaron Bensimon, Genomic Vision’s co-founder and CEO, added “We are delighted to join Euronext’s Paris market. We would like to thank all of our shareholders, old and new, who helped us achieve this milestone — and who will now be accompanying us as we roll out our technology in Europe and expand its scope to new pathologies.”

To celebrate the continuous trading in its shares that started today, Aaron Bensimon and his team rang the bell marking the opening of Euronext’s financial markets.



[1]Small and medium-sized entreprises
[2]
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.6 trillion in market capitalisation as of end December 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. - All rights reserved.